Claus, S. P. (2017) Will gut microbiota help design the next generation of GLP1-based therapies for type 2 diabetes? Cell Metabolism, 26 (1). pp. 6-7. ISSN 1550-4131 doi: 10.1016/j.cmet.2017.06.009
Abstract/Summary
Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance. In a recent issue of Cell Metabolism, Grasset et al. (2017) demonstrated that GLP-1 sensitivity is modulated by gut bacteria through NO signaling in the enteric nervous system.
Altmetric Badge
| Item Type | Article |
| URI | https://reading-clone.eprints-hosting.org/id/eprint/73545 |
| Identification Number/DOI | 10.1016/j.cmet.2017.06.009 |
| Refereed | Yes |
| Divisions | Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences > Food Microbial Sciences Research Group |
| Publisher | Elsevier |
| Download/View statistics | View download statistics for this item |
University Staff: Request a correction | Centaur Editors: Update this record
Download
Download